A Man with Intermittent Abdominal Pain, Liver Injury, and Renal Impairment
Baocheng Deng,Wei Cui,Pei Liu
DOI: https://doi.org/10.1053/j.gastro.2016.11.054
IF: 29.4
2017-01-01
Gastroenterology
Abstract:Question: A 45-year-old man presented with intermittent abdominal pain, dark urine, and constipation for 6 months. Laboratory tests of the initial episode showed total bilirubin 109.9 μmol/L (reference range, 3.4-20.5), alanine aminotransferase 3500 U/L (reference range, 9-40), aspartate aminotransferase 1860 U/L (reference range, 15-40), gamma-glutamyl transferase 763 U/L (reference range, 10-60), and alkaline phosphatase 164 U/L (reference range, 45-125). The patient was discharged with abnormal liver biochemistry. For the past 4 weeks, the abdominal pain became diffuse, and the episodes lasted from a few minutes to several hours. Upon examination, the skin and sclera were mildly icteric; there was diffuse abdominal pain on palpation. A purple-blue line (Figure A) at the edge of the gums was noticed. He had consumed 100-g hot yellow rice wine (10 g alcohol) from the tin pot per day for 20 years. One year prior, he acquired a new tin pot to replace the old one. Laboratory tests on admission showed mild abnormal liver biochemistry, a normocytic anemia with a hemoglobin of 118 g/L (reference range, 130-175), creatinine 138 μmol/L (reference range, 59-104), and blood urea nitrogen 10.5 mmol/L (reference range, 2.85-7.14). Abdominal anteroposterior radiograph showed multiple air–fluid levels and dilated bowel (Figure B). On day 3 of the admission, a repeated abdominal anteroposterior radiograph showed the air–fluid levels significantly decreased (Figure C) after administration with fasting water and gastrointestinal decompression. The liver pathology result showed edema of liver cells and intrahepatic cholestasis (Figure D, E). On day 4, the patient’s 26-year-old daughter complained of dark urine, and liver biochemistry showed acute liver injury. She had consumed 50 g hot yellow rice wine (5 g alcohol) from the tin pot per day for 10 years. What is the diagnosis? See the Gastroenterology web site (www.gastrojournal.org) for more information on submitting your favorite image to Clinical Challenges and Images in GI. The clinical presentation suggested the colonic obstruction was pseudo-obstruction. Features of this case that are consistent with lead poisoning include colonic pseudo-obstruction, constipation, anemia, liver injury, and renal impairment. The purple-blue line in Figure A was a lead line, which is a clinical sign in patients with chronic lead poisoning. Blood lead levels of the father and daughter were found to be 187 and 97 μg/dL (reference range, 0-10), respectively. The component analysis revealed the new tin pot contained 3.8% lead. The patients stopped exposure to lead, and received injections of calcium disodium edetate. The patient’ abdominal pain, laboratory tests, and serum lead level were normalized 3 months later. Lead poisoning can affect major organ systems in the body, including the hematopoietic, gastrointestinal, liver, renal, lung, and nervous systems. Excess levels of lead results in production of free radicals, which subsequently cause oxidative damage to cellular components, including DNA and cell membranes.1Flora S.J. Mittal M. Mehta A. Heavy metal induced oxidative stress and its possible reversal by chelation therapy.Indian J Med Res. 2008; 128 (501–423)PubMed Google Scholar Hepatotoxicity can be caused by lead exposure, which varies from asymptomatic enzyme elevations to fulminant hepatitis. Lead-induced acute hepatotoxicity is quite rare in humans. The hepatic morphopathologic findings of lead poisoning is not specific.2Verheij J. Voortman J. van Nieuwkerk C.M. et al.Hepatic morphopathologic findings of lead poisoning in a drug addict: a case report.J Gastrointest Liver Dis. 2009; 18: 225-227PubMed Google Scholar Identification of the lead source is important. The first and primary treatment for lead poisoning is removal from exposure. The indication and type of pharmacologic treatment are determined by patient’s age, clinical symptomatology, and blood lead levels. When the blood lead level is ≥100 μg/dL, chelating therapy is always necessary and should be started parenterally in a hospital.3Kianoush S. Sadeghi M. Balali-Mood M. Recent advances in the clinical management of lead poisoning.Acta Med Iran. 2015; 53: 327-336PubMed Google Scholar